ResMed Inc (RMD) stock

RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026Score 21/3011% below fair value

$229.94−22.89 (-9.05%)

Close on Oct 30, 2026Market cap $33.17BP/E 22.0Yield 1.04%

Earnings

ResMed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Jan 28, 2027

Q2 FY2027 · estimated, after the close

Revenue, Q1 FY2027

$1.40B

+7.7% on a year earlier

non-GAAP diluted EPS, Q1 FY2027

$2.91

$2.55 a year earlier

Latest guidance

Issued

Oct 29, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of ResMed's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q2 FY2027ended Dec 31, 2026	Jan 28, 2027Expected	–	–	–	–	–
Q1 FY2027ended Sep 30, 2026	Oct 29, 2026after the close	$1.40B	+7.7%	$2.92	$2.91	Release
Q4 FY2026ended Jun 30, 2026	Aug 6, 2026after the close	$1.50B	+15.4%	$2.64	$2.95	Release
Q3 FY2026ended Mar 31, 2026	Apr 30, 2026after the close	$1.40B	+7.7%	$2.74	$2.86	Release
Q2 FY2026ended Dec 31, 2025	Jan 29, 2026after the close	$1.40B	+7.7%	$2.68	$2.81	Release
Q1 FY2026ended Sep 30, 2025	Oct 30, 2025after the close	$1.30B	+8.3%	$2.37	$2.55	Release
Q4 FY2025ended Jun 30, 2025	Jul 31, 2025after the close	$1.30B	+8.3%	$2.58	$2.55	Release
Q3 FY2025ended Mar 31, 2025	Apr 23, 2025after the close	$1.30B	+8.3%	$2.48	$2.37	Release
Q2 FY2025ended Dec 31, 2024	Jan 30, 2025after the close	$1.30B	+8.3%	$2.34	$2.43	Release
Q1 FY2025ended Sep 30, 2024	Oct 24, 2024after the close	$1.20B	+9.1%	$2.11	$2.20	Release
Q4 FY2024ended Jun 30, 2024	Aug 1, 2024after the close	$1.20B	+9.1%	$1.98	$2.08	Release
Q3 FY2024ended Mar 31, 2024	Apr 25, 2024after the close	$1.20B	+7.4%	$2.04	$2.13	Release
Q2 FY2024ended Dec 31, 2023	Jan 24, 2024after the close	$1.20B	+16.1%	$1.42	$1.88	Release
Q1 FY2024ended Sep 30, 2023	Oct 26, 2023after the close	$1.10B	+15.8%	$1.49	$1.64	Release
Q4 FY2023ended Jun 30, 2023	Aug 3, 2023after the close	$1.10B	+20.3%	–	–	Release
Q3 FY2023ended Mar 31, 2023	Apr 27, 2023after the close	$1.12B	+29.2%	$1.58	$1.68	Release
Q2 FY2023ended Dec 31, 2022	Jan 26, 2023after the close	$1.03B	+15.5%	$1.53	$1.66	Release
Q1 FY2023ended Sep 30, 2022	Oct 27, 2022after the close	$950.30M	+5.1%	$1.43	$1.51	Release
Q4 FY2022ended Jun 30, 2022	Aug 11, 2022after the close	$914.70M	–	$1.33	$1.49	Release
Q3 FY2022ended Mar 31, 2022	Apr 28, 2022after the close	$864.50M	–	$1.22	$1.32	Release
Q2 FY2022ended Dec 31, 2021	Jan 27, 2022after the close	$894.90M	–	$1.37	$1.47	Release
Q1 FY2022ended Sep 30, 2021	Oct 28, 2021after the close	$904.00M	–	$1.39	$1.51	Release
Q4 FY2021ended Jun 30, 2021	Aug 5, 2021after the close	–	–	–	–	Release
Q3 FY2021ended Mar 31, 2021	Apr 29, 2021after the close	–	–	–	–	Release
Q2 FY2021ended Dec 31, 2020	Jan 28, 2021after the close	–	–	–	–	Release
Q1 FY2021ended Sep 30, 2020	Oct 29, 2020after the close	–	–	–	–	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

ResMed's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Core Constant Currencynon-GAAP	FY2027	+5% – +7%	–	New	Oct 29, 2026
ReportedGAAP	FY2027	$5.75B – $5.85B	–	New	Oct 29, 2026
Non-GAAP Diluted EPSnon-GAAP	FY2027	$12.00 – $12.25	–	New	Oct 29, 2026
capital to be returned to shareholders through share repurchases and dividends	FY2027	$1.85B	–	New	Aug 6, 2026

Guidance history

Every forecast ResMed put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 29, 2026	Non-GAAP Diluted EPS	FY2027	$12.00 – $12.25	New
Oct 29, 2026	Core Constant Currency	FY2027	+5% – +7%	New
Oct 29, 2026	Reported	FY2027	$5.75B – $5.85B	New
Aug 6, 2026	capital to be returned to shareholders through share repurchases and dividends	FY2027	$1.85B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.